Skip to main content

Table 1 Clinical manifestations at disease onset of KawaCOVID Group (KCG) of patients and Kawasaki Disease Group (KDG) of patients

From: Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey

  KCG (n = 53) N (%) KDG (n = 96) N (%) p value
Skin involvement
 Maculo-papular rash 21 (40) 59 (62) 0·001
 Erythema multiforme 4 (8) 7 (7) 1
 Scarlatiniform rash 0 (0) 8 (8) 0·05
 Hands and feet erythema/oedema 15 (28) 38 (40) 0·17
 Hands and feet desquamation 1 (2) 6 (6) 0·42
 Perineal Erythema/Desquamation 0 (0) 8 (8) 0·05
Mucosal involvement
 Cheilitis 14 (26) 46 (48) 0·01
 Pharyngeal and/or oral erhytema 24 (45) 49 (51) 0·50
 Strawberry tongue 4 (8) 14 (15) 0·29
Ocular involvement
 Non Secretive Conjunctivitis 27 (51) 67 (70) 0·02
Neurological involvement
 Headache 5 (9) 3 (3) 0·13
 Consciousness abnormalities 4 (8) 1 (1) 0·05
 Aseptic meningitis 3 (6) 1 (1) 0·13
 Irritability 8 (15) 34 (35) 0·01
Gastrointestinal involvement
 Diarrhea 28 (53) 11 (12) < 0·0001
 Vomiting 14 (26) 8 (8) 0·003
 Abdominal pain 17 (32) 10 (10) 0·001
 Gallbladder hydrops 2 (4) 3 (3) 1
Respiratory involvement
 Dyspnea 8 (15) 1 (1) 0·001
 Tachypnea 12 (23) 4 (4) 0·001
 Cough 3 (6) 10 (10) 0·38
 Rhinitis 0 (0) 5 (5) 0·16
 Lobar pneumonia 3 (6) 2 (2) 0·35
 Interstitial pneumonia 20 (37) 17 (18) 0·01
 O2 supplementation 14 (28) 2 (2) < 0·0001
 Ventilation 6 (12) 0 (0) 0·003
Osteoarticular involvement
 Arthritis and/or arthralgia 6 (11) 13 (14) 0·7